NUR 615 MIDTERM EXAM (UTICA) QUESTIONS
AND CORRECT ANSWERS (VERIFIED ANSWERS)
PLUS RATIONALES 2026/2027 Q&A | INSTANT
DOWNLOAD PDF
Core Domains
Pharmacokinetics and Pharmacodynamics
Drug Metabolism and CYP450 Interactions
Prescriptive Authority and Regulatory Compliance
Pharmacogenomics and Individualized Therapy
Autonomic Pharmacology
Drug Development and FDA Regulation
Adverse Drug Reactions and Hypersensitivity
Special Populations: Geriatrics, Pediatrics, and Pregnancy
Ethics and Professional Standards in Prescribing
Introduction
The NUR 615 Midterm Exam assesses advanced pharmacology knowledge essential for safe and effective
prescribing in advanced practice nursing. This examination evaluates foundational pharmacokinetic
principles, pharmacodynamic mechanisms, drug metabolism pathways, and regulatory frameworks
governing prescriptive authority. Questions are structured in multiple-choice and scenario-based formats
emphasizing clinical application, critical thinking, and decision-making in diverse patient populations.
Candidates must demonstrate competency in drug selection, dosing calculations, adverse effect
monitoring, and integration of pharmacogenomic considerations into practice. The exam reflects the
complexity of contemporary pharmacotherapeutics and the clinical judgment required for advanced
practice nursing.
SECTION ONE: QUESTIONS 1–100
Question 1
A patient with a documented genetic polymorphism resulting in CYP2D6 poor metabolizer status is
prescribed codeine for pain management. Which outcome should the advanced practice nurse
anticipate?
A. Enhanced analgesic effect with increased risk of respiratory depression
B. Adequate pain relief with standard dosing
C. Inadequate pain relief due to impaired conversion to morphine
D. Rapid elimination of codeine with no therapeutic effect
C. Inadequate pain relief due to impaired conversion to morphine
, RATIONALE: Codeine is a prodrug requiring conversion to morphine by CYP2D6 for analgesic activity.
Poor metabolizers convert codeine inefficiently, resulting in inadequate pain relief. Enhanced analgesia
and respiratory depression occur in ultra-rapid metabolizers who convert codeine to morphine too
rapidly. Impaired conversion does not cause rapid elimination.
Question 2
A 72-year-old patient with decreased total body water and increased body fat requires a hydrophilic
drug. How will these age-related changes most likely affect the drug's volume of distribution?
A. Increased volume of distribution for water-soluble drugs
B. Decreased volume of distribution for water-soluble drugs
C. No change in volume of distribution
D. Increased volume of distribution for lipid-soluble drugs only
B. Decreased volume of distribution for water-soluble drugs
RATIONALE: Decreased total body water reduces the volume into which hydrophilic drugs distribute,
resulting in a smaller volume of distribution and potentially higher serum concentrations. This age-
related change increases the risk of drug toxicity. Lipid-soluble drugs distribute into increased body fat
with greater volume of distribution.
Question 3
An APRN is prescribing a drug that is a known CYP3A4 inducer to a patient already taking a CYP3A4
substrate. Which effect should the nurse anticipate?
A. Increased substrate serum concentration with toxicity risk
B. No change in substrate metabolism
C. Decreased substrate serum concentration and potential loss of efficacy
D. Immediate enzyme inhibition with rapid drug accumulation
C. Decreased substrate serum concentration and potential loss of efficacy
RATIONALE: CYP450 inducers increase enzyme synthesis and activity, accelerating metabolism of
substrate drugs and reducing their serum concentrations. This may result in therapeutic failure.
Increased substrate concentrations occur with enzyme inhibitors, not inducers.
Question 4
A drug with a half-life of 12 hours is administered via continuous infusion. Approximately how long will it
take to reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 48 to 60 hours
D. 120 hours
C. 48 to 60 hours
, RATIONALE: Steady state is reached after approximately 4 to 5 half-lives. With a half-life of 12 hours,
steady state occurs in 48 to 60 hours (12 × 4 = 48; 12 × 5 = 60). This principle guides dosing interval
decisions and timing of serum level monitoring.
Question 5
A patient is prescribed a medication with a narrow therapeutic index. Which monitoring approach is
most appropriate?
A. No monitoring required due to predictable kinetics
B. Therapeutic drug monitoring with peak and trough levels
C. Monitoring only if adverse effects occur
D. Routine monitoring every 6 months
B. Therapeutic drug monitoring with peak and trough levels
RATIONALE: Drugs with narrow therapeutic indices, such as digoxin, phenytoin, and warfarin,
require therapeutic drug monitoring to ensure levels remain within the therapeutic range while avoiding
toxicity. The narrow margin between effective and toxic concentrations necessitates close monitoring.
Question 6
Which FDA pregnancy labeling system replaced the former letter categories (A, B, C, D, X)?
A. The Pregnancy Risk Assessment System
B. The Pregnancy and Lactation Labeling Rule (PLLR)
C. The Teratogen Classification System
D. The Maternal Safety Index
B. The Pregnancy and Lactation Labeling Rule (PLLR)
RATIONALE: The PLLR replaced the outdated letter categories with narrative summaries providing
detailed risk information in three subsections: Pregnancy, Lactation, and Females and Males of
Reproductive Potential. This rule addresses criticism that the letter system was overly simplistic.
Question 7
A patient with cirrhosis requires medication management. Which pharmacokinetic process is most
significantly impaired?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: The liver is the primary site of drug metabolism. Cirrhosis reduces hepatic enzyme
activity and blood flow, impairing biotransformation and leading to drug accumulation and toxicity risk.
While other processes may be affected, metabolism is most directly compromised in liver disease.
, Question 8
Which statement accurately describes the mechanism of action of a partial agonist?
A. It produces a maximal response equal to a full agonist
B. It blocks all receptor activity
C. It produces a submaximal response despite full receptor occupancy
D. It has no affinity for receptors
C. It produces a submaximal response despite full receptor occupancy
RATIONALE: Partial agonists bind to receptors and activate them but produce a lower maximal
response than full agonists, even at 100% receptor occupancy. They have both affinity and intrinsic
activity, unlike antagonists which have affinity but no intrinsic activity.
Question 9
A patient receiving long-term corticosteroid therapy requires gradual tapering rather than abrupt
discontinuation. This practice prevents which type of adverse drug reaction?
A. Type A dose-dependent reaction
B. Type B idiosyncratic reaction
C. Type C chronic use reaction
D. Type D delayed reaction
C. Type C chronic use reaction
RATIONALE: Type C reactions occur with prolonged drug use and include hypothalamic-pituitary-
adrenal axis suppression from chronic corticosteroids. Abrupt discontinuation can precipitate adrenal
crisis. Type C reactions require gradual tapering and monitoring for withdrawal effects.
Question 10
An APRN is determining the appropriate route of administration for a drug with extensive first-pass
metabolism. Which route would maximize bioavailability?
A. Oral
B. Rectal
C. Sublingual
D. Enteral
C. Sublingual
RATIONALE: Sublingual administration bypasses the hepatic portal circulation by absorbing directly
into systemic circulation through the oral mucosa, avoiding first-pass metabolism. Oral and enteral
routes undergo significant hepatic metabolism before reaching systemic circulation.
Question 11
Which CYP450 enzyme metabolizes approximately 50% of all marketed drugs?
AND CORRECT ANSWERS (VERIFIED ANSWERS)
PLUS RATIONALES 2026/2027 Q&A | INSTANT
DOWNLOAD PDF
Core Domains
Pharmacokinetics and Pharmacodynamics
Drug Metabolism and CYP450 Interactions
Prescriptive Authority and Regulatory Compliance
Pharmacogenomics and Individualized Therapy
Autonomic Pharmacology
Drug Development and FDA Regulation
Adverse Drug Reactions and Hypersensitivity
Special Populations: Geriatrics, Pediatrics, and Pregnancy
Ethics and Professional Standards in Prescribing
Introduction
The NUR 615 Midterm Exam assesses advanced pharmacology knowledge essential for safe and effective
prescribing in advanced practice nursing. This examination evaluates foundational pharmacokinetic
principles, pharmacodynamic mechanisms, drug metabolism pathways, and regulatory frameworks
governing prescriptive authority. Questions are structured in multiple-choice and scenario-based formats
emphasizing clinical application, critical thinking, and decision-making in diverse patient populations.
Candidates must demonstrate competency in drug selection, dosing calculations, adverse effect
monitoring, and integration of pharmacogenomic considerations into practice. The exam reflects the
complexity of contemporary pharmacotherapeutics and the clinical judgment required for advanced
practice nursing.
SECTION ONE: QUESTIONS 1–100
Question 1
A patient with a documented genetic polymorphism resulting in CYP2D6 poor metabolizer status is
prescribed codeine for pain management. Which outcome should the advanced practice nurse
anticipate?
A. Enhanced analgesic effect with increased risk of respiratory depression
B. Adequate pain relief with standard dosing
C. Inadequate pain relief due to impaired conversion to morphine
D. Rapid elimination of codeine with no therapeutic effect
C. Inadequate pain relief due to impaired conversion to morphine
, RATIONALE: Codeine is a prodrug requiring conversion to morphine by CYP2D6 for analgesic activity.
Poor metabolizers convert codeine inefficiently, resulting in inadequate pain relief. Enhanced analgesia
and respiratory depression occur in ultra-rapid metabolizers who convert codeine to morphine too
rapidly. Impaired conversion does not cause rapid elimination.
Question 2
A 72-year-old patient with decreased total body water and increased body fat requires a hydrophilic
drug. How will these age-related changes most likely affect the drug's volume of distribution?
A. Increased volume of distribution for water-soluble drugs
B. Decreased volume of distribution for water-soluble drugs
C. No change in volume of distribution
D. Increased volume of distribution for lipid-soluble drugs only
B. Decreased volume of distribution for water-soluble drugs
RATIONALE: Decreased total body water reduces the volume into which hydrophilic drugs distribute,
resulting in a smaller volume of distribution and potentially higher serum concentrations. This age-
related change increases the risk of drug toxicity. Lipid-soluble drugs distribute into increased body fat
with greater volume of distribution.
Question 3
An APRN is prescribing a drug that is a known CYP3A4 inducer to a patient already taking a CYP3A4
substrate. Which effect should the nurse anticipate?
A. Increased substrate serum concentration with toxicity risk
B. No change in substrate metabolism
C. Decreased substrate serum concentration and potential loss of efficacy
D. Immediate enzyme inhibition with rapid drug accumulation
C. Decreased substrate serum concentration and potential loss of efficacy
RATIONALE: CYP450 inducers increase enzyme synthesis and activity, accelerating metabolism of
substrate drugs and reducing their serum concentrations. This may result in therapeutic failure.
Increased substrate concentrations occur with enzyme inhibitors, not inducers.
Question 4
A drug with a half-life of 12 hours is administered via continuous infusion. Approximately how long will it
take to reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 48 to 60 hours
D. 120 hours
C. 48 to 60 hours
, RATIONALE: Steady state is reached after approximately 4 to 5 half-lives. With a half-life of 12 hours,
steady state occurs in 48 to 60 hours (12 × 4 = 48; 12 × 5 = 60). This principle guides dosing interval
decisions and timing of serum level monitoring.
Question 5
A patient is prescribed a medication with a narrow therapeutic index. Which monitoring approach is
most appropriate?
A. No monitoring required due to predictable kinetics
B. Therapeutic drug monitoring with peak and trough levels
C. Monitoring only if adverse effects occur
D. Routine monitoring every 6 months
B. Therapeutic drug monitoring with peak and trough levels
RATIONALE: Drugs with narrow therapeutic indices, such as digoxin, phenytoin, and warfarin,
require therapeutic drug monitoring to ensure levels remain within the therapeutic range while avoiding
toxicity. The narrow margin between effective and toxic concentrations necessitates close monitoring.
Question 6
Which FDA pregnancy labeling system replaced the former letter categories (A, B, C, D, X)?
A. The Pregnancy Risk Assessment System
B. The Pregnancy and Lactation Labeling Rule (PLLR)
C. The Teratogen Classification System
D. The Maternal Safety Index
B. The Pregnancy and Lactation Labeling Rule (PLLR)
RATIONALE: The PLLR replaced the outdated letter categories with narrative summaries providing
detailed risk information in three subsections: Pregnancy, Lactation, and Females and Males of
Reproductive Potential. This rule addresses criticism that the letter system was overly simplistic.
Question 7
A patient with cirrhosis requires medication management. Which pharmacokinetic process is most
significantly impaired?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
C. Metabolism
RATIONALE: The liver is the primary site of drug metabolism. Cirrhosis reduces hepatic enzyme
activity and blood flow, impairing biotransformation and leading to drug accumulation and toxicity risk.
While other processes may be affected, metabolism is most directly compromised in liver disease.
, Question 8
Which statement accurately describes the mechanism of action of a partial agonist?
A. It produces a maximal response equal to a full agonist
B. It blocks all receptor activity
C. It produces a submaximal response despite full receptor occupancy
D. It has no affinity for receptors
C. It produces a submaximal response despite full receptor occupancy
RATIONALE: Partial agonists bind to receptors and activate them but produce a lower maximal
response than full agonists, even at 100% receptor occupancy. They have both affinity and intrinsic
activity, unlike antagonists which have affinity but no intrinsic activity.
Question 9
A patient receiving long-term corticosteroid therapy requires gradual tapering rather than abrupt
discontinuation. This practice prevents which type of adverse drug reaction?
A. Type A dose-dependent reaction
B. Type B idiosyncratic reaction
C. Type C chronic use reaction
D. Type D delayed reaction
C. Type C chronic use reaction
RATIONALE: Type C reactions occur with prolonged drug use and include hypothalamic-pituitary-
adrenal axis suppression from chronic corticosteroids. Abrupt discontinuation can precipitate adrenal
crisis. Type C reactions require gradual tapering and monitoring for withdrawal effects.
Question 10
An APRN is determining the appropriate route of administration for a drug with extensive first-pass
metabolism. Which route would maximize bioavailability?
A. Oral
B. Rectal
C. Sublingual
D. Enteral
C. Sublingual
RATIONALE: Sublingual administration bypasses the hepatic portal circulation by absorbing directly
into systemic circulation through the oral mucosa, avoiding first-pass metabolism. Oral and enteral
routes undergo significant hepatic metabolism before reaching systemic circulation.
Question 11
Which CYP450 enzyme metabolizes approximately 50% of all marketed drugs?
